Sort
10,766 grants matching “checkpoint inhibitor”
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy
$1,221,684Kenneth Olivier · Boston Immune Technologies And Therapeutics, Inc. · R44 · FY2023 · CA
Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation
$1,219,852Siu Kit Lam · Immunophotonics, Inc. · R44 · FY2023 · CA
Molecular Genetic Study of Stem Cells, Cancer Stem Cells, and Stem Cell Aging
$1,219,721Steven Hou · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Studies of Receptor Interactions and Effects of Alarmins
$1,219,341Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Molecular Determinants of Chromosome Transmission and Cell Cycle Regulation
$1,216,171Munira Basrai · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Mechanisms of non-classical multidrug resistance in cancer
$1,215,165Michael Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
INVESTIGATING DECOY-RESISTANT IL-18 PLUS IMMUNE CHECKPOINT INHIBITORS IN PRECLINICAL MURINE AND EX VIVO PATIENT-DERIVED MODELS OF RENAL CELL CARCINOMA
$1,214,375Yale Univ · · FY2024 · Defense Health Agency
Activating Cell Death Pathways in Breast Cancer Cells
$1,213,551Stanley Lipkowitz · Division Of Clinical Sciences - Nci · ZIA · FY2025 · CA
Genetically Engineered Mouse Models to Study Melanoma Genesis and Progression
$1,211,771Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor Response
$1,211,771Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,211,401Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Studies of Receptor Interactions and Effects of Alarmins
$1,207,540Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
$1,205,769Brendan D Curti · Providence Portland Medical Center · R01 · FY2025 · CA
Identification of genetic interactors of Brca2
$1,205,586Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Signal Transduction Events and the Regulation of Cell Growth
$1,205,526Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2022 · CA
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1
$1,205,048Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2019 · AI
Pediatric Oncology Branch Behavioral Science Core
$1,203,016John Glod · Division Of Basic Sciences - Nci · ZID · FY2023 · CA
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$1,202,994Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Novel Approach to High-Throughput Identification and Characterization of Neoantigen-Specific T-Cell Receptors to Guide Immunotherapy Development.
$1,202,794Magali Soumillon · Flexomics Llc · R44 · FY2022 · CA
Photodynamic Priming of Cancer and Image-guidance for Optimal Immune Response
$1,202,445Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2023 · CA
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
$1,201,880Andrea Califano · Columbia University Health Sciences · U01 · FY2021 · CA
Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles
$1,200,245Elias Sayour · University Of Florida · R01 · FY2025 · CA
Signal Transduction Events and the Regulation of Cell Growth
$1,199,893Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2021 · CA
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
$1,198,246Alexander B Sigalov · Signablok, Inc. · R44 · FY2020 · CA
A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)
$1,197,275Lorin K Johnson · Glycyx Mor, Inc. · R44 · FY2025 · CA